涉及药物治疗推荐的重症监护临床实践指南质量评价
该研究系统检索PubMed、MEDLINE和Embase,纳入2012至2022年发表、涉及药物治疗推荐的重症监护临床实践指南,共21部,用AGREE II工具由2名评价者独立评价质量。21部指南共1604条推荐,强推荐116条(7.23%),每部指南强推荐数0至31条;9部(43%)指南有至少1名药师作者。AGREE II各域中范围与目的(0.88)、严谨性(0.80)、清晰性(0.84)、编辑独立性(0.86)评分较高,利益相关方参与(0.69)和适用性(0.49)评分最低;药师参与指南制定与利益相关方参与域评分显著更高相关(P=0.0356)。作者认为应让药师参与涉及药物治疗推荐的重症指南制定。
要点
- 21部重症指南共1604条推荐,强推荐仅116条(7.23%),每部指南强推荐数0至31条。
- AGREE II适用性域平均分最低(0.49;95%CI 0.43-0.55),利益相关方参与域次低(0.69;95%CI 0.63-0.75)。
- 范围与目的(0.88;95%CI 0.85-0.92)、严谨性(0.80;95%CI 0.77-0.83)、清晰性(0.84;95%CI 0.81-0.87)、编辑独立性(0.86;95%CI 0.79-0.94)评分较高。
- 9部(43%)指南有至少1名药师作者,药师参与与利益相关方参与域评分显著更高相关(P=0.0356)。
- 作者认为,涉及药物治疗推荐的重症指南应让药师参与制定。
适用人群与场景
- 2012至2022年发表的、涉及药物治疗推荐的重症监护临床实践指南,共21部
研究设计与关键结果
- 系统检索PubMed、MEDLINE和Embase,纳入2012至2022年发表、涉及药物治疗推荐的重症监护临床实践指南21部,由2名评价者独立用AGREE II工具评价质量。
- 21部指南共1604条推荐,每部指南推荐数2至250条;强推荐共116条,占7.23%,每部指南强推荐数0至31条。
- 9部(43%)指南有至少1名药师作者。
- AGREE II各域平均分:范围与目的0.88(95%CI 0.85-0.92)、严谨性0.80(95%CI 0.77-0.83)、清晰性0.84(95%CI 0.81-0.87)、编辑独立性0.86(95%CI 0.79-0.94)、利益相关方参与0.69(95%CI 0.63-0.75)、适用性0.49(95%CI 0.43-0.55)。
- 药师参与指南制定与利益相关方参与域评分显著更高相关(P=0.0356)。
证据类型、等级与局限
- 证据类型:对临床实践指南进行质量评价的系统检索研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,涉及药物治疗推荐的重症指南应让药师参与制定。
- 作者指出,所评价指南的强推荐不足10%,且适用性(即把推荐付诸实践的建議或工具)和利益相关方参与(即纳入所有相关群体的代表)存在担忧。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To assess the quality of critical care clinical practice guidelines (CPGs) involving pharmacotherapy recommendations.
METHODS: A systematic electronic search was performed using PubMed, MEDLINE, and Embase for critical care CPGs published between 2012 and 2022 and involving pharmacotherapy recommendations. The Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument was employed to appraise CPG quality through independent assessment by 2 appraisers.
RESULTS: Twenty-one CPGs were evaluated. The number of recommendations in each guideline ranged from 2 to 250, with a total of 1,604 recommendations. The number of strong (vs weak) recommendations in each guideline ranged from 0 to 31, with a total of 116 strong recommendations, or 7.23% of the total number of recommendations. There was at least 1 pharmacist author for 9 (43%) of the guidelines. The AGREE II domains for which mean quality scores of evaluated guidelines were highest were scope and purpose (0.88; 95% CI, 0.85-0.92), rigor of development (0.80; 95% CI, 0.77-0.83), clarity of presentation (0.84; 95% CI, 0.81-0.87), and editorial independence (0.86; 95% CI, 0.79-0.94), while those for which mean scores were lowest were stakeholder involvement (0.69; 95% CI, 0.63-0.75) and applicability (0.49; 95% CI, 0.43-0.55). Involvement of a pharmacist in CPG development was associated with significantly higher scoring for stakeholder involvement (P = 0.0356).
CONCLUSION: Strong recommendations accounted for less than 10% of the recommendations in the evaluated CPGs. Moreover, there are concerns related to guideline applicability (ie, advice or tools for putting recommendations into practice) and stakeholder involvement (ie, inclusion of individuals from all relevant groups). It is important to involve pharmacists in CPGs with pharmacotherapy recommendations.
参考来源
- Edwards C, Lam J, Gardiner J, et al. Quality of critical care clinical practice guidelines involving pharmacotherapy recommendations. Am J Health Syst Pharm. 2022. PMID: 35848948. doi:10.1093/ajhp/zxac193
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。